Currently, Aurobindo Pharma, Glenmark and Zydus are in the process of recalling their products in the US market due to manufacturing issues. While the concerns around Aurobindo Pharma and Glenmark Pharma pertain to the "deviation from the current good manufacturing practices (cGMP)", in the case of Zydus, wrong labelling is the reason for recall. Experts said the recent instances of recall could impact the Indian pharma industry which is already facing the heat globally due to a spate of quality issues over the past two years.
Denne historien er fra December 17, 2024-utgaven av Financial Express Lucknow.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra December 17, 2024-utgaven av Financial Express Lucknow.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Poverty of ambition
Zero tariffs for US drugs cost little but Indian firms must look beyond branded generics, seek R&D-driven growth
In trade war with US, China deploys food as weapon
CHINESE TARIFFS ON a slew of American farm products have officially come into effect, the latest retaliation in the unfolding trade war between the world's top two economies.
Mark Carney wins race to lead Liberal Party, and Canada
FORMER CENTRAL BANKER Mark Carney won the race to become leader of Canada's ruling Liberal Party and will succeed Justin Trudeau as prime minister, official results showed on Sunday.
Demat account additions in Feb at 21-month low
THE ADDITION OF demat accounts in February fell to a 21-month low at 2.26 million, even though their total number surpassed the 190-million mark, according to data from CDSL and NSDL.
Cars24 Forays Into New Car Sales With Super App
Cars24 on Monday entered the new car sales space by launching a platform that aggregates automobile dealerships and manufacturers.
Indices fall on tariff concerns; VIX jumps
SHARES ENDED LOWER on Monday, with the broader market seeing sharper cuts, as concerns over US tariffs and the ongoing market decline kept investors on edge.
Sun to buy Checkpoint for $355 mn
THE DEAL WILL be made through an upfront cash payment of $4.10 per common share, a premium of about 66% to Checkpoint's last close on Friday, Sun Pharma said in an exchange filing.
2W dealers anxious as new norms from Apr 1; no clarity on old stock
The next stage of regulatory compliance for two- and three-wheelers is set to kick-start on April 1, 2025.
Data find clues to hidden water-ice on the moon
Chandrayaan-3 Data Findings
Govt's FY25 spending to exceed revised estimate
THE CENTRE ON Monday sought Parliament's approval for net additional spending of ₹51,463 crore in the second batch of supplementary demand for grants for FY25, which could lead to government expenditure exceeding the revised estimate (RE) of ₹47.16 lakh crore, sources said.
